Tonix Pharmaceuticals Holding (TNXP) Non-Current Assets (2010 - 2026)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly Non-Current Assets of $50.7 million for Q1 2026, up 17.2% year-over-year from $43.3 million in Q1 2025, and up 5.07% quarter-over-quarter from $48.3 million in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Non-Current Assets (2010 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Non-Current Assets history runs 17 years deep, the most recent figure standing at $50.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 17.2% year-over-year to $50.7 million; the TTM figure through Mar 2026 stood at $187.2 million (up 5.99% YoY), while the FY2025 annual figure was $48.3 million, up 10.04% from the prior year.
- Non-Current Assets for Q1 2026 stood at $50.7 million, up from $48.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $108.4 million in Q2 2023, with the low at $43.3 million in Q1 2025.
- The 5-year median for Non-Current Assets is $70.7 million (2022), against an average of $72.3 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets soared 609.63% in 2022, then slumped 58.86% in 2024.
- Tonix Pharmaceuticals Holding's Non-Current Assets stood at $94.9 million in 2022, then grew by 12.41% to $106.7 million in 2023, then plunged by 58.86% to $43.9 million in 2024, then climbed by 10.04% to $48.3 million in 2025, then advanced by 5.07% to $50.7 million in 2026.
- Business Quant data shows TNXP's Non-Current Assets at $50.7 million in Q1 2026, $48.3 million in Q4 2025, and $44.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn | 50.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.66 Mn |
| Mar 31, 2026 | 50.74 Mn |
| Dec 31, 2025 | 48.30 Mn |
| Sep 30, 2025 | 44.37 Mn |
| Jun 30, 2025 | 43.82 Mn |
| Mar 31, 2025 | 43.30 Mn |
| Dec 31, 2024 | 43.89 Mn |
| Sep 30, 2024 | 44.45 Mn |
| Jun 30, 2024 | 45.02 Mn |
| Mar 31, 2024 | 105.25 Mn |
| Dec 31, 2023 | 106.69 Mn |
| Sep 30, 2023 | 107.95 Mn |
| Jun 30, 2023 | 108.41 Mn |
| Mar 31, 2023 | 95.36 Mn |
| Dec 31, 2022 | 94.91 Mn |
| Sep 30, 2022 | 91.51 Mn |
| Jun 30, 2022 | 84.42 Mn |
| Mar 31, 2022 | 70.73 Mn |
| Dec 31, 2021 | 51.85 Mn |
| Sep 30, 2021 | 19.69 Mn |